Crossject (ALCJ) - Net Assets

Latest as of June 2025: €-1.12 Million EUR ≈ $-1.31 Million USD

Based on the latest financial reports, Crossject (ALCJ) has net assets worth €-1.12 Million EUR (≈ $-1.31 Million USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€31.38 Million ≈ $36.68 Million USD) and total liabilities (€32.49 Million ≈ $37.99 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Crossject liquid asset ratio to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric	Value
Current Net Assets	€-1.12 Million
% of Total Assets	-3.56%
Annual Growth Rate	N/A
5-Year Change	N/A
10-Year Change	-130.38%
Growth Volatility	506.54

Crossject - Net Assets Trend (2010–2024)

This chart illustrates how Crossject's net assets have evolved over time, based on quarterly financial data. Also explore total assets of Crossject for the complete picture of this company's asset base.

Annual Net Assets for Crossject (2010–2024)

The table below shows the annual net assets of Crossject from 2010 to 2024. For live valuation and market cap data, see how much is Crossject worth.

Year	Net Assets	Change
2024-12-31	€-2.67 Million ≈ $-3.13 Million	+49.27%
2023-12-31	€-5.27 Million ≈ $-6.16 Million	-296.17%
2022-12-31	€2.69 Million ≈ $3.14 Million	+149.01%
2021-12-31	€-5.48 Million ≈ $-6.41 Million	-384.99%
2020-12-31	€-1.13 Million ≈ $-1.32 Million	-137.50%
2019-12-31	€3.01 Million ≈ $3.52 Million	+82.16%
2018-12-31	€1.65 Million ≈ $1.93 Million	-72.81%
2017-12-31	€6.09 Million ≈ $7.11 Million	-3.15%
2016-12-31	€6.28 Million ≈ $7.35 Million	-28.57%
2015-12-31	€8.80 Million ≈ $10.29 Million	-39.26%
2014-12-31	€14.48 Million ≈ $16.93 Million	+1428.46%
2013-12-31	€947.65K ≈ $1.11 Million	+149.75%
2012-12-31	€-1.90 Million ≈ $-2.23 Million	+11.29%
2011-12-31	€-2.15 Million ≈ $-2.51 Million	+74.40%
2010-12-31	€-8.39 Million ≈ $-9.81 Million	--

Equity Component Analysis

This analysis shows how different components contribute to Crossject's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have grown by 1388676100.0% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2024)

Component	Amount	Percentage
Common Stock	€4.55 Million	%
Other Comprehensive Income	€972.00K	%
Other Components	€7.19 Million	%
Total Equity	€-2.67 Million	100.00%

Crossject Competitors by Market Cap

The table below lists competitors of Crossject ranked by their market capitalization.

Company	Market Cap
Merck Tbk JK:MERK	$110.25 Million
Eusu Holdings KO:000700	$110.30 Million
Sedana Medical AB ST:SEDANA	$110.32 Million
Se Gyung Hi Tech Co.Ltd KQ:148150	$110.33 Million
Yuhwa Sec KO:003460	$110.23 Million
Cube Entertainment Inc KQ:182360	$110.23 Million
Nonthavej Hospital Public Company Limited BK:NTV	$110.21 Million
Macrogen Inc KQ:038290	$110.15 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Crossject's equity between the two most recent reporting periods.

Equity Growth Insights

From 2023 to 2024, total equity changed from -5,269,000 to -2,673,000, a change of 2,596,000.
Net loss of 12,795,000 reduced equity.
Share repurchases of 878,000 reduced equity.
New share issuances of 15,085,000 increased equity.
Other comprehensive income increased equity by 962,999.
Other factors increased equity by 221,001.

Equity Change Factors (2023 to 2024)

Factor	Impact	Contribution
Net Income	€-12.79 Million	-478.68%
Share Repurchases	€878.00K	-32.85%
Share Issuances	€15.09 Million	+564.35%
Other Comprehensive Income	€963.00K	+36.03%
Other Changes	€221.00K	+8.27%
Total Change	€-	%

Book Value vs Market Value Analysis

This analysis compares Crossject's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2010-12-31	€-1.89	€1.90	x
2011-12-31	€-0.48	€1.90	x
2012-12-31	€-0.43	€1.90	x
2013-12-31	€0.18	€1.90	x
2014-12-31	€2.18	€1.90	x
2015-12-31	€1.32	€1.90	x
2016-12-31	€0.86	€1.90	x
2017-12-31	€0.68	€1.90	x
2018-12-31	€0.12	€1.90	x
2019-12-31	€0.15	€1.90	x
2020-12-31	€-0.05	€1.90	x
2021-12-31	€-0.24	€1.90	x
2022-12-31	€0.06	€1.90	x
2023-12-31	€-0.14	€1.90	x
2024-12-31	€-0.06	€1.90	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Crossject utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): 0.00%
The company may be facing challenges in efficiently utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: -310.94%
• Asset Turnover: 0.13x
• Equity Multiplier: 0.00x
Recent ROE (0.00%) is above the historical average (-130.37%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2010	0.00%	-2058.76%	0.07x	0.00x	€-3.28 Million
2011	0.00%	237.75%	0.22x	0.00x	€1.76 Million
2012	0.00%	-261.88%	0.14x	0.00x	€-735.29K
2013	-192.33%	-194.74%	0.17x	5.96x	€-1.92 Million
2014	-29.94%	-313.04%	0.08x	1.27x	€-5.78 Million
2015	-64.64%	-358.57%	0.11x	1.58x	€-6.57 Million
2016	-106.03%	-468.32%	0.10x	2.27x	€-7.29 Million
2017	-125.06%	-235.32%	0.18x	2.91x	€-8.22 Million
2018	-647.41%	-438.26%	0.12x	12.18x	€-10.88 Million
2019	-238.02%	-1434.74%	0.02x	8.13x	€-7.48 Million
2020	0.00%	-203.22%	0.14x	0.00x	€-9.73 Million
2021	0.00%	-1184.87%	0.03x	0.00x	€-10.19 Million
2022	-552.05%	-1169.50%	0.03x	16.26x	€-11.36 Million
2023	0.00%	-5957.24%	0.01x	0.00x	€-8.11 Million
2024	0.00%	-310.94%	0.13x	0.00x	€-12.53 Million

Industry Comparison

This section compares Crossject's net assets metrics with peer companies in the Medical Instruments & Supplies industry.

Industry Context

Industry: Medical Instruments & Supplies
Average net assets among peers: $384,297,948
Average return on equity (ROE) among peers: -244.56%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Crossject (ALCJ)	€-1.12 Million	0.00%	N/A	$110.24 Million
I.Ceram SA (ALICR)	$10.64 Million	-9.43%	0.23x	$155.73K
Safe Orthopaedics SA (ALSAF)	$398.00K	-1685.68%	36.39x	$135.92K
Spineway (ALSPW)	$4.62 Million	-36.05%	1.43x	$6.50 Million
Amplitude Surgical SAS (AMPLI)	$118.76 Million	-14.86%	1.08x	$299.85 Million
Sartorius Stedim Biotech SA (DIM)	$647.22 Million	18.23%	0.65x	$17.02 Billion
EssilorLuxottica S. A. (EL)	$1.91 Billion	17.25%	0.64x	$98.12 Billion
Bonyf NV (MLBON)	$2.64 Million	-1.38%	0.26x	$2.90 Million

About Crossject

PA:ALCJ France Medical Instruments & Supplies

Market Cap

$116.85 Million

€99.95 Million EUR

Market Cap Rank

#18801 Global

#283 in France

Share Price

€1.90

Change (1 day)

-0.63%

52-Week Range

€1.02 - €2.69

All Time High

€10.40